Cellaviva delivers stem cells to treat serious blood disease

April 1, 2022

Cordblood contains blood stem cells and is routinely used to treat severe diseasesof the blood and immune system. The treatment is similar to bone marrow stem celltherapy and the most common use of cord blood is sibling donation for thetreatment of childhood leukaemia.

NextCellowns the Cellaviva biobank, which has been helping pregnant parents savestem cells in connection with childbirth since 2015. The umbilical cord bloodthat is saved is the blood that remains in the placenta and umbilical cordafter the baby is born and the cord has been cut. In addition, a piece of theumbilical cord is also collected to grow connective tissue-forming stem cells.Haematopoietic stem cells can mature into all types of blood cells and immunecells, while connective tissue stem cells can mature into other tissues such ascartilage, fat and bone.

“ Thepurpose of preserving stem cells is not the saving itself, but to have rapidaccess to the highest quality stem cells in case of serious disease. Ourorganisation contributes to the development of new therapies and the expansionof treatment options for affected patients. Ultimately, it's about savinglives," says Mathias Svahn, vd NextCell.

Thecollection of stem cells from the umbilical cord does not alter the birthingprocess in any way and is risk-free. Currently, there are over 80 healthconditions with cord blood stem cells as an approved treatment option. In addition,experimental treatments using cord blood and cord tissue stem cells are beingevaluated for conditions such as cerebral palsy and type 1 diabetes. NextCellis conducting its own clinical trials with cells from donated umbilical cordsfor the treatment of type 1 diabetes and severe pneumonia caused by COVID-19.

For more information aboutCellaviva, please contact:

SofieFalk-Jansson, Commercial Director

Tel: 08-735 2010

E-mail: info@cellaviva.se

Webpage: www.cellaviva.se | www.cellaviva.dk

Instagram: https://www.instagram.com/cellaviva/

Facebook: https://www.facebook.com/cellavivasverige/

For more information about NextCell PharmaAB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel:08-735 5595

E-mail: info@nextcellpharma.com

Websites:
www.nextcellpharma.com
www.cellaviva.se
www.cellaviva.dk

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

About NextCell Pharma AB

NextCell is a phase II cell therapy company withthe drug candidate ProTrans for the treatment of type 1 diabetes. The focus isto take ProTrans to market approval via a Phase III study. ProTrans is inaddition to diabetes, used in two clinical trials for Covid-19, in Örebro andMontreal (Canada). The company is in the processes of establishing its own GMPfacility for production of ProTrans. The GMP facility is expected to be readyfor production of smaller quantities of ProTrans in 2023. NextCell furthermoreowns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva,Scandinavia's largest stem cell bank for family saving stem cells fromumbilical cord blood and umbilical cord tissue with permission from the SwedishHealth and Social Care Inspectorate (IVO).

‍

Download attachment Read full press release on Cision (external link)

2019-11-07

Correction: Notice to attend the Annual General Meeting

NextCell Pharma AB ("NextCell") announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been published. Compared to the press release published this morning, corrections have been made regarding the Market Abuse Regulation label. The information is not subject to the Market Abuse Regulation. The annual general meeting will be held on December 5, 2019 at 10.00 at Novum, Hälsovägen 7, Huddinge. The notice has been published in Svenska Dagbladet and Post and Inrikes Tidningar as well as on the company's website, www.nextcellpharma.com. The Annual Report and

Read more Read more

2019-11-07

Notice to attend the Annual General Meeting

NextCell Pharma AB ("NextCell") announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been published. The annual general meeting will be held on December 5, 2019 at 10.00 at Novum, Hälsovägen 7, Huddinge. The notice has been published in Svenska Dagbladet and Post and Inrikes Tidningar as well as on the company's website, www.nextcellpharma.com. The Annual Report and Audit Report will be available three weeks before the Meeting, November 14, on the Company's website, www.nextcellpharma.com. This information is the information that NextCell Pharma AB

Read more Read more

2019-10-31

Year-end report 2018-09-01 - 2019-08-31

Nextcell Pharma AB ("NXTCL") today announces the year-end report for the 2018/2019 fiscal year (2018-08-31 2019-08-31) Twelve months (2018-09-01 until 2019-08-31) · Operating income amounted to SEK 1 964 132 (655 413). · Operating result amounted to SEK -21 450 784 (-14 032 294). · Earnings per share* amounted to SEK -1.36 (-0.61). · Cash and bank amounted to SEK 20 128 185 (3 115 876). · Solidity** amounted to 85.9 (59.2) %. Fourth quarter (2019-06-01 until 2019-08-31) · Operating income amounted to SEK 551 708 (127 868). · Operating result

Read more Read more

2019-10-25

NextCell invests in the Danish Cellaviva operations with a new Copenhagen office

NextCell Pharma AB ("NextCell") today announces they are investing for growth in Cellaviva's Danish operations with the opening of a new Copenhagen office. In October, Cellaviva's new office was opened in Copenhagen, located in Kløvebyen. The Copenhagen office is primarily intended to be a hub for the Danish Cellaviva business with the opportunity to host customers, hold training sessions etc. The purpose is also to enable increased exposure and presence for NextCell in the Öresund region. [image] [image]

Read more Read more

2019-10-01

All patients in ProTrans-Repeat are now treated

NextCell Pharma AB ("NextCell") announces that another significant milestone has been reached when the last patient, as part of the ProTrans-Repeat active treatment group, today has received their treatment. This implies that all treatments, related to the two ongoing ProTrans studies, have been completed. NextCell is conducting two parallel clinical trials with the drug candidate ProTrans, with the aim to treat diabetes type-1. ProTrans-Repeat, which was initiated in May 2019, is a continuation trial of ProTrans-1 dose escalation part with the aim of maximizing data collection on repeated

Read more Read more

2019-09-24

Last patient, last visit completed in the dose escalation part

NextCell Pharma AB (NextCell) is today announcing that the last patient in the dose escalation part of the clinical trial ProTrans-1 for diabetes is completed. The last patient was today at the last visit and has now left the trial. ProTrans-1 is a two-part phase I / II clinical trial where the phase I part evaluates safety for three doses. All nine patients have now been followed up for 12 months and have left the study. As previously communicated, all 15 patients in the phase II part of ProTrans-1 have been treated and will be followed for 12 months. The second part is randomized,

Read more Read more

2019-09-12

Update on the ongoing clinical trials

NextCell Pharma AB (NextCell) is today providing a status update regarding its two ongoing clinical trials, presented at the Nordic Life Science days in Malmö. All patients in ProTrans-1 were treated by June 2019 and 8 out of 9 patients in the dose escalation part have already left the trial after 12 months follow-up. The ProTrans-Repeat has included 5 out of 18 patients. NextCell is conducting two parallel clinical trials with the drug candidate ProTrans, with the aim to treat type-1 diabetes. A single dose of ProTrans is given and the patients own ability to produce insulin is compared

Read more Read more

2019-08-16

NextCell Pharma files another patent application

NextCell Pharma AB ("NextCell") today announces that they have filed a new patent application to the Swedish Patent and Registration Office. The patent relates to the Company's proprietary selection algorithm, now with extended and tailored analyses for diseases and conditions affecting the central nervous system. The application was submitted to the Swedish Patent and Registration Agency on August 15 and is formulated to cover the general production of all types of mesenchymal stem cell products derived from multiple donors and cells selected by the selection algorithm. Furthermore, the

Read more Read more